| Literature DB >> 32843980 |
Kang-Lian Tan1,2, Hai-Jun Deng1, Zhi-Qiang Chen2, Ting-Yu Mou1, Hao Liu1, Run-Sheng Xie2, Xue-Min Liang2, Xiao-Hua Fan2, Guo-Xin Li1.
Abstract
BACKGROUND?>: Laparoscopic surgery for rectal cancer is commonly performed in China. However, compared with open surgery, the effectiveness of laparoscopic surgery, especially the long-term survival, has not been sufficiently proved. METHODS?>: Data of eligible patients with non-metastatic rectal cancer at Nanfang Hospital of Southern Medical University and Guangdong Provincial Hospital of Chinese Medicine between 2012 and 2014 were retrospectively reviewed. Long-term survival outcomes and short-term surgical safety were analysed with propensity score matching between groups.Entities:
Keywords: laparoscopic surgery; open surgery; propensity score matching; rectal cancer
Year: 2020 PMID: 32843980 PMCID: PMC7434561 DOI: 10.1093/gastro/goaa046
Source DB: PubMed Journal: Gastroenterol Rep (Oxf)
Figure 1.Flow diagram of patient disposition
Baseline characteristics of the study population
| Characteristic | Total cohort | Matched cohort | ||||
|---|---|---|---|---|---|---|
| Laparoscopic group ( | Open group ( |
| Laparoscopic group ( | Open group ( |
| |
| Age, years, mean ± SD | 59.0 ± 13.2 | 62.4 ± 13.1 | 0.024 | 61.2 ± 13.0 | 62.0 ±13.2 | 0.641 |
| Gender, | 0.540 | 0.469 | ||||
| Male | 159 (65.4) | 67 (62.0) | 68 (66.0) | 63 (61.2) | ||
| Female | 84 (34.6) | 41 (38.0) | 35 (34.0) | 40 (38.8) | ||
| BMI, kg/m2, mean ± SD | 22.5 ± 3.6 | 21.9 ± 3.1 | 0.155 | 21.8 ± 3.9 | 21.9 ± 3.1 | 0.759 |
| Preoperative CEA, | 0.014 | 0.770 | ||||
| ≤5 ng/mL | 188 (77.4) | 70 (64.8) | 66 (64.1) | 68 (66.0%) | ||
| >5 ng/mL | 55 (22.6) | 38 (35.2) | 37 (35.9) | 35 (34.0%) | ||
| Tumor location, | 0.850 | 0.840 | ||||
| Upper rectum | 109 (44.8) | 45 (47.7) | 40 (38.8) | 42 (40.8) | ||
| Middle rectum | 101 (41.6) | 48 (44.4) | 46 (44.7) | 47 (45.6) | ||
| Lower rectum | 33 (13.6) | 15 (13.9) | 17 (16.5) | 14 (13.6) | ||
| Tumor stage, | 0.492 | 0.673 | ||||
| I | 56 (23.0) | 19 (17.6) | 21 (20.4) | 18 (17.5) | ||
| II | 94 (38.7) | 43 (39.8) | 36 (35.0) | 42 (40.8) | ||
| III | 93 (38.3) | 46 (42.6) | 46 (44.6) | 43 (41.7) | ||
SD, standard deviation; BMI, body mass index; CEA, carcinoembryonic antigen.
Operative and pathological results in matched cohorts
| Variable | Laparoscopic group ( | Open group ( |
|
|---|---|---|---|
| Surgical procedure, | 0.112 | ||
| Low anterior resection | 80 (77.6) | 90 (87.4) | |
| Abdominoperineal resection | 22 (21.4) | 12 (11.6) | |
| Hartmann’s procedure | 1 (1.0) | 1 (1.0) | |
| Protective ileostomy, | 25 (24.3) | 18 (17.5) | 0.230 |
| Operative time, min, Median (IQR) | 150 (128–217) | 210 (170–250) | 0.000 |
| Intraoperative blood loss, mL, Median (IQR) | 50 (50–100) | 100 (100–150) | 0.019 |
| Hospital stay, day, Median (IQR) | 16 (13–19) | 19 (17–19) | 0.000 |
| Tumor grade, | 0.663 | ||
| Well | 4 (3.9) | 3 (2.9) | |
| Moderate | 85 (82.5) | 90 (87.5) | |
| Poor/others | 14 (13.6) | 10 (9.7) | |
| Harvested lymph nodes, | 0.129 | ||
| <12 | 36 (35.0) | 26 (25.2) | |
| ≥12 | 67 (65.0) | 77 (74.8) | |
| Lymphovascular invasion, | 6 (5.8) | 19 (18.4) | 0.006 |
| Perineural invasion, | 4 (3.9) | 8 (7.8) | 0.234 |
| Tumor deposits, | 5 (4.9) | 13 (12.6) | 0.048 |
| Post-operative complications, | 10 (9.7) | 11 (10.7) | 0.818 |
| Wound infection | 0 (0) | 4 (3.9) | 0.121 |
| Ileus | 1 (1.0) | 0 (0) | 1.000 |
| Urinary dysfunction | 1 (1.0) | 0 (0) | 1.000 |
| Anastomosis leakage | 6 (5.8) | 3 (2.9) | 0.498 |
| Intra-abdominal bleeding | 1 (1.0) | 1 (1.0) | 1.000 |
| Pneumonia | 2 (1.9) | 4 (3.9) | 0.683 |
| Cardiac event | 0 (0) | 2 (1.9) | 0.498 |
| Reoperation, | 2 (1.9) | 2 (1.9) | 1.000 |
| Mortality, | 1 (1.0) | 0 (0) | 1.000 |
IQR, interquartile range.
Figure 2.Survival curve after laparoscopic surgery vs open surgery in matched cohorts
Figure 3.Subgroup analysis of overall survival in matched cohorts
Multivariate analysis for OS and RFS in matched cohorts
| Variable | OS | RFS | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI |
| HR | 95% CI |
| |
| Preoperative CEA (>5 vs ≤5 ng/mL) | 2.43 | 1.38–4.29 | 0.002 | 2.27 | 1.31–3.93 | 0.003 |
| Number of harvested lymph nodes (≥12 vs <12) | 0.48 | 0.27–0.85 | 0.011 | 0.53 | 0.30–0.92 | 0.024 |
| Perineural invasion (yes vs no) | 2.88 | 1.29–6.43 | 0.010 | 3.23 | 1.51–6.91 | 0.002 |
OS, overall survival; RFS, relapse-free survival; CEA, carcinoembryonic antigen; HR, hazard ratio; CI, confidence interval.